Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polymyxin B plus tigecycline in MBL-producing carbapenem-resistant Enterobacteriaceae bloodstream infection
ChiCTR2000035119Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polymyxin B and tigecycline in bloodstream infection (BSI), sponsored by Sir Run-Run Shaw Hospital. Primary endpoints: pharmacokinetic parameters of polymyxin B, efficacy and 1 more. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
polymyxin Btigecycline
03
Conditions
bloodstream infection (BSI)
Beyond the preview
Go deeper on ChiCTR2000035119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035119.